Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group

Abstract excerpt

= .14). These findings illustrate the significant differences in the spectrum of kinase alterations and clinical outcome of Ph-like ALL based on presenting clinical features and establish that genomic alterations potentially targetable with approved kinase inhibitors are less frequent in SR than in HR ALL.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Childhood Cancer Survivors' Quality of Life
• Share to Acute Lymphoblastic Leukemia research
• Share to Chronic Myeloid Leukemia Treatments